Latest Ratios: P/E Ratio -29.4x · EV/EBITDA N/A · ROE N/A. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $143M | $288M | — | — | — | — | — |
| Enterprise Value | $160M | $306M | — | — | — | — | — |
| P/E Ratio → | -29.38 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — |
| ROA | -34.4% | -34.4% | -41.3% | -51.8% | -72.9% | -37.7% | -14.9% |
| ROIC | — | — | — | — | — | — | — |
| ROCE | — | — | — | — | — | -47.1% | -34.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -1.03 | -1.03 | -1.92 | -4.81 | -7.67 | -4.03 | -2.94 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.45 | 0.45 | 0.02 | 0.13 | 0.19 | 0.42 | 1.08 |
| Quick Ratio | 0.45 | 0.45 | 0.02 | 0.13 | 0.19 | 0.42 | 1.08 |
| Cash Ratio | 0.03 | 0.03 | 0.01 | 0.01 | 0.06 | 0.38 | 0.73 |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $73M | $76M | $76M | $76M | $76M | $72M |
Imminent liquidity and dilution
According to recent financial disclosures, the company's current ratio has plummeted to a negligible 0.02, signaling an acute liquidity crisis that leaves virtually no buffer against the escalating costs of Phase III clinical trials or unexpected regulatory delays in the near term for the firm.
The current ratio of 0.02 indicates that current assets are insufficient to cover even a fraction of short-term liabilities, suggesting the company is operating on a day-to-day basis. This extreme lack of liquidity warrants immediate investor caution, as it implies that the firm may be unable to meet its contractual obligations to clinical research organizations without an immediate capital injection.
Based on reported figures, the company carries significant debt obligations against a negative equity position, creating a leverage profile that appears fundamentally unsustainable and suggests that debt is being utilized for survival rather than strategic growth initiatives as the firm navigates its late-stage clinical development pipeline.
The presence of debt in a pre-revenue entity with negative equity suggests that the company has exhausted traditional equity financing avenues and is relying on debt to bridge the gap to potential commercialization. Investors should monitor the interest coverage ratios, which remain deeply negative, indicating that the firm lacks the operational cash flow to service its existing debt burden independently.
As indicated by the company's financial statements, the cash conversion cycle is heavily impacted by erratic vendor settlement patterns, with accounts payable days fluctuating significantly across recent quarters, reflecting the firm's struggle to manage its limited cash resources while maintaining its critical research and development operations.
The volatility in accounts payable suggests that the company may be stretching its payment terms to preserve cash, a common but risky tactic for firms in a liquidity crunch. This behavior may eventually strain relationships with key suppliers and clinical partners, potentially jeopardizing the timeline for the MCS-2 clinical trial.
The market may be systematically misinterpreting the company's book value, as the reported asset base is heavily offset by substantial liabilities, rendering traditional price-to-book metrics largely irrelevant for assessing the true economic viability of this pre-revenue biotechnology firm in its current clinical-stage development phase.
Investors should avoid using P/B ratios, as they fail to account for the high probability of further equity dilution required to sustain operations. Instead, analysts should focus on the 'Cash Runway' and 'Net Burn Rate' to evaluate the company's survival prospects, as these metrics provide a more accurate reflection of the firm's immediate financial risk than static balance sheet figures.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MENS stock.
Jyong Biotech Ltd. Ordinary Shares's current P/E ratio is -29.4x. This places it at the 50th percentile of its historical range.
Based on historical data, Jyong Biotech Ltd. Ordinary Shares is trading at a P/E of -29.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.